| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
42,603 |
35,162 |
$3.51M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
5,224 |
5,217 |
$513K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
5,509 |
5,409 |
$500K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,213 |
2,939 |
$364K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
3,013 |
3,011 |
$294K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
14,228 |
14,095 |
$268K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,644 |
1,644 |
$173K |
| 86328 |
|
3,804 |
1,977 |
$145K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
29,133 |
25,812 |
$142K |
| 87070 |
|
29,618 |
26,112 |
$137K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,643 |
2,506 |
$127K |
| 87184 |
|
29,623 |
26,137 |
$114K |
| 69210 |
|
1,769 |
1,718 |
$79K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,491 |
2,311 |
$57K |
| 90677 |
|
786 |
784 |
$57K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
5,945 |
2,828 |
$52K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
16,064 |
14,975 |
$45K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
603 |
581 |
$44K |
| 99051 |
|
7,281 |
6,907 |
$39K |
| 99188 |
|
2,187 |
2,187 |
$24K |
| 83655 |
|
3,301 |
3,295 |
$24K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
494 |
475 |
$23K |
| 87428 |
|
1,057 |
1,009 |
$21K |
| 99381 |
|
180 |
180 |
$18K |
| 90461 |
|
3,355 |
3,345 |
$15K |
| 97802 |
|
1,888 |
1,884 |
$14K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
136 |
135 |
$14K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
153 |
153 |
$11K |
| 81002 |
|
5,813 |
5,714 |
$8K |
| 90697 |
|
617 |
617 |
$8K |
| 99177 |
|
3,659 |
3,655 |
$7K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
25 |
25 |
$3K |
| 99382 |
|
13 |
13 |
$1K |
| 90686 |
|
599 |
584 |
$815.16 |
| 90716 |
|
69 |
69 |
$400.00 |
| 99173 |
|
201 |
199 |
$262.01 |
| 90670 |
|
833 |
833 |
$257.99 |
| 96127 |
|
38 |
38 |
$196.52 |
| 99050 |
|
20 |
20 |
$164.10 |
| 90715 |
|
53 |
53 |
$131.15 |
| 90707 |
|
43 |
43 |
$100.00 |
| 90672 |
|
298 |
288 |
$86.29 |
| 36416 |
|
13,520 |
12,442 |
$85.14 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
13 |
13 |
$78.00 |
| 99401 |
|
628 |
628 |
$77.54 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
12 |
12 |
$60.03 |
| 90633 |
|
66 |
66 |
$41.67 |
| 90744 |
|
50 |
50 |
$31.47 |
| 90656 |
|
67 |
67 |
$23.53 |
| 90660 |
|
19 |
19 |
$21.65 |
| 90688 |
|
12 |
12 |
$21.56 |
| 90698 |
|
164 |
164 |
$0.00 |
| 90723 |
|
83 |
83 |
$0.00 |
| 90619 |
|
203 |
203 |
$0.00 |
| 90680 |
|
310 |
309 |
$0.00 |
| 99000 |
|
672 |
635 |
$0.00 |
| 90696 |
|
12 |
12 |
$0.00 |
| 85018 |
|
47 |
46 |
$0.00 |
| 90647 |
|
27 |
27 |
$0.00 |
| 90710 |
|
17 |
17 |
$0.00 |
| 90734 |
|
32 |
32 |
$0.00 |
| 90700 |
|
58 |
58 |
$0.00 |
| 90671 |
|
77 |
77 |
$0.00 |